Contrarian Investors: Don’t Expect a Sudden Rebound in Valeant Pharmaceuticals Intl Inc.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) appears to be getting cheaper by the day. Is it finally time to initiate a contrarian position?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in the midst of a transformation overhaul as its new CEO Joseph Papa looks to clean up the mess that Michael Pearson and the old management team left behind. Valeant has lost almost 97% of its value as the stock continues to fall further into the abyss. Unfortunately for many contrarian investors, the stock continued its tumble into the single digits.

It’s undervalued, but is it safe to buy shares?

Many pundits believe that Valeant is extremely undervalued and that the company could offer contrarians the opportunity for a rebound of a lifetime. Valeant owns terrific core assets, but the fire sale of non-core assets is far from over, as the management team looks to raise money to chip away at the mountain of debt.

I think Valeant is close to a bottom, but if you’re hungry for a rebound, you’ve got to be realistic. Valeant probably isn’t going to skyrocket overnight or quadruple over the next three years as some of the more bullish analysts out there believe. If you’re got a stomach for volatility and you can afford to wait five years or more, then Valeant could be an intriguing rebound play. Bill Ackman had horrible timing when he first initiated a position. And maybe his decision to dump the stock was just as poorly timed.

Valeant recently released the first real positive piece of news in a long time. The company raised its full-year adjusted EBITDA forecast, and the company is on schedule to reach its target of paying back $5 billion in debt by February 2018. This is promising news, and I believe the rally that followed was completely warranted.

Where is the stock heading from here?

The rally has since run out of steam, and Valeant appears to be picking up negative momentum again. There’s a stigma surrounding Valeant which I don’t think will go away with a new management team. The possibility of a company name change was also brought up, but would this attract investors? Or is it just a cheap trick that investors will see through?

I’m not sure, but it appears that Valeant will require a steady stream of good news to keep the stock moving higher; otherwise, in the short to medium term, I think the stock will continue to decline by default.

I’m a huge fan of the core assets owned by Valeant, and I believe they are absurdly undervalued, but I think it’ll take many years to attract investors back to the company and its new, legitimate business model.

I would recommend picking up shares in very small increments on the way down, but only if you truly believe in Joseph Papa and the new management team. I think he’s the right man for the job, but keep in mind, he’s not a miracle worker. There’s still a lot of cleaning up to do, and a sustainable rally may be a year or more away.

Stay smart. Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

money goes up and down in balance
Dividend Stocks

This 6% Dividend Stock Is My Top Pick for Immediate Income

This Canadian stock has resilient business model, solid dividend payment and growth history, and a well-protected yield of over 6%.

Read more »

Canadian energy stocks are rising with oil prices
Energy Stocks

Outlook for Cenovus Energy Stock in 2025

A large-cap energy stock and TSX30 winner is a screaming buy for its bright business outlook and visible growth potential.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Stock Market

CRA: Here’s the TFSA Contribution Limit for 2025

The TFSA is a tax-sheltered account that allows you to hold diversified asset classes at a low cost.

Read more »

Hourglass and stock price chart
Tech Stocks

1 Canadian Stock Ready to Surge Into 2025

There is a lot of uncertainty about the market in general as we move closer to the following year, but…

Read more »

think thought consider
Stock Market

Billionaires Are Selling Apple Stock and Picking up This TSX Stock Instead

Billionaires like Warren Buffett continue to trim stakes in Apple stock, with others picking up this long-term stock instead.

Read more »

ways to boost income
Dividend Stocks

1 Excellent TSX Dividend Stock, Down 25%, to Buy and Hold for the Long Term

Down 25% from all-time highs, Tourmaline Oil is a TSX dividend stock that offers you a tasty yield of 5%…

Read more »

canadian energy oil
Energy Stocks

Is Baytex Energy Stock a Good Buy?

Baytex just hit a 12-month low. Is the stock now oversold?

Read more »

Start line on the highway
Dividend Stocks

1 Incredibly Cheap Canadian Dividend-Growth Stock to Buy Now and Hold for Decades

CN Rail (TSX:CNR) stock is incredibly cheap, but should investors join insiders by buying the dip?

Read more »